Literature DB >> 2115647

The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas.

J X Wu1, P M Carpenter, C Gresens, R Keh, H Niman, J W Morris, D Mercola.   

Abstract

The expression of fos protein was examined in 30 cases of human osteosarcoma as formalin-fixed and paraffin-embedded tissue sections using two monoclonal antibodies and, for five cases, as frozen sections using 3 polyclonal antibodies. Nuclear antibody labeling intensities were determined either by visual scoring (3 pathologists) or by microdensitometry and included over 700 tumor, 350 normal and 150 benign tissue observations. Visual scores were shown to be linear with optical density with a correlation coefficient of 0.97. Analysis of the osteosarcoma cases at one antibody concentration revealed two groups: a minority (39%) with a low average visual score of 2 +/- 0.2 which was very similar to benign and normal tissues, and a majority (61%) with an average score of 3.1 +/- 0.3. The difference is highly significant (t-test), P less than or equal to 0.01. The results were supported by an analysis of partial immunotitration curves using a curve-fitting procedure which yielded estimates of FOSo (maximum relative fos protein concentration) which were ca. 150% increased for the majority tumor group compared to the minority group or benign or normal tissues. In previous studies of v-sis transformed cells, which exhibit ca. 300% over-expression of c-fos protein as observed here, antisense techniques were used to show that over-expression leads to increased growth and loss of contact inhibition. Thus the combined results suggest that steady state c-fos protein is significantly elevated in, and may contribute to, the aggressive growth properties of a majority of human osteosarcomas.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2115647

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  35 in total

1.  Establishment of an osteogenic cell line derived from adult mouse bone marrow stroma by use of a recombinant retrovirus.

Authors:  E Mathieu; G Schoeters; F vander Plaetse; J Merregaert
Journal:  Calcif Tissue Int       Date:  1992-04       Impact factor: 4.333

Review 2.  Fibrous dysplasia of bone: the bone lesion unmasked.

Authors:  F R Singer
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

3.  Chondrocytes as a specific target of ectopic Fos expression in early development.

Authors:  H Watanabe; K Saitoh; T Kameda; M Murakami; Y Niikura; S Okazaki; Y Morishita; S Mori; Y Yokouchi; A Kuroiwa; H Iba
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

4.  Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma.

Authors:  Virna D Leaner; Jeffrey F Chick; Howard Donninger; Ilona Linniola; Arnulfo Mendoza; Chand Khanna; Michael J Birrer
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

Review 5.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

6.  Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy.

Authors:  Bekim Sadikovic; Paul Thorner; Susan Chilton-Macneill; Jeff W Martin; Nilva K Cervigne; Jeremy Squire; Maria Zielenska
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

7.  c-fos oncogene underexpression in salivary gland tumors as measured by in situ hybridization.

Authors:  C Birek; E Lui; I Dardick
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

Review 8.  A review of clinical and molecular prognostic factors in osteosarcoma.

Authors:  Jonathan C M Clark; Crispin R Dass; Peter F M Choong
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-27       Impact factor: 4.553

9.  Cause and consequences of genetic and epigenetic alterations in human cancer.

Authors:  B Sadikovic; K Al-Romaih; J A Squire; M Zielenska
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

10.  ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells.

Authors:  G Valabrega; F Fagioli; S Corso; E Madon; A Brach del Prever; E Biasin; A Linari; M Aglietta; S Giordano
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.